In this study, we analyzed the difference in TIME in CRC patients with and without KRAS mutations, to explore the potential role of TIME in KRAS-mutated CRC patients, therefore, it may help to improve the clinical benefit of ICIs in KRAS-mutated CRC by regulating and optimizing TIME in the future clinical practice. The gene discussed is KRAS; the disease is colorectal carcinoma.